Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation

Dosing of Target-Specific Oral Anticoagulants in Special Populations

(2015) Amanda M. Morrill et al.   ANNALS OF PHARMACOTHERAPY

Decreasedin vitroanticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis

(2015) Wilma Potze et al.   HEPATOLOGY

Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study

(2015) Federica Cerini et al.   HEPATOLOGY

An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics

(2015) Jeanne Mendell et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan

(2015) K.-J. Ng et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Idarucizumab for Dabigatran Reversal

(2015) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

(2015) Deborah M. Siegal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial

(2015) Martin H. Prins et al.   THROMBOSIS RESEARCH

The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis

(2014) C. Chai-Adisaksopha et al.   BLOOD

Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis

(2014) Daniel Caldeira et al.   HEART

Treating thrombosis in cirrhosis patients with new oral agents: Ready or not?

(2014) Nicolas M. Intagliata et al.   HEPATOLOGY

Treatment of acute portal vein thrombosis by nontraditional anticoagulation

(2014) Melissa Martinez et al.   HEPATOLOGY

Rivaroxaban postmarketing risk of liver injury

(2014) Stefan Russmann et al.   JOURNAL OF HEPATOLOGY

Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis

(2014) Wilma Potze et al.   PLoS One

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

(2013) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis

(2013) Wilma Potze et al.   BRITISH JOURNAL OF HAEMATOLOGY

Coagulation in Liver Disease: A Guide for the Clinician

(2013) Patrick G. Northup et al.   Clinical Gastroenterology and Hepatology

Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment

(2013) Jochen Graff et al.   CLINICAL PHARMACOKINETICS

Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis

(2013) Armando Tripodi et al.   JOURNAL OF HEPATOLOGY

Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding

(2013) Nicolas M. Intagliata et al.   LIVER INTERNATIONAL

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

(2013) Maureane Hoffman et al.   THROMBOSIS AND HAEMOSTASIS

Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis

(2012) María Gabriela Delgado et al.   Clinical Gastroenterology and Hepatology

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

(2012) Erica Villa et al.   GASTROENTEROLOGY

The Coagulopathy of Chronic Liver Disease

(2011) Armando Tripodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pro-coagulant imbalance in patients with chronic liver disease

(2010) Armando Tripodi et al.   JOURNAL OF HEPATOLOGY

Low-molecular-weight heparin in patients with advanced cirrhosis

(2010) Lars P. Bechmann et al.   LIVER INTERNATIONAL

Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered

(2009) Marco Senzolo et al.   Internal and Emergency Medicine

Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study

(2008) Kirstine Kobberøe Søgaard et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

(2008) Joachim Stangier et al.   JOURNAL OF CLINICAL PHARMACOLOGY